|
|
|
| home | genetic news | bioinformatics | biotechnology | literature | journals | ethics | positions | events | sitemap |
NCI Study Estimates More Than 2 Million Women Could Benefit From Tamoxifen
|
More than 10 million women in the United States have a high enough risk of developing breast cancer that they could consider taking the breast cancer chemoprevention drug tamoxifen, according to Andrew N. Freedman, Ph.D., and his colleagues at the National Cancer Institute (NCI). When the scientists examined this group of women using a risk-benefit analysis of the drug, they found that more than 2 million women would be likely to derive overall benefit from the drug without undue risks. The results were reported in the April 2, 2003, issue of the Journal of the National Cancer Institute.
CONTACT:
Message posted by: Rashmi Nemade
Bookmark and Share this page (what is this?)
Social bookmarking allows users to save and categorise a personal collection of bookmarks and share them with others. This is different to using your own browser bookmarks which are available using the menus within your web browser. Use the links below to share this article on the social bookmarking site of your choice. Read more about social bookmarking at Wikipedia - Social Bookmarking |
PrimerBank: a centralized database of primers for QPCR The NCBI BioSystems database: a centralized resource for biomolecular systems Phenomizer: a freely available tool for clinical genetics BioGPS: a centralized online resource for gene annotation Brain Adaptations to Sensory Loss Sequencing Small Chips A Stroke Against Stroke Inhibition Present in Absences Assessing Natural Memory Variant Associated with Alcoholic Liver Disease Parkinson's Gene Mutated in Cancer more news ... |
Generated by News Editor 2.0 by Kai Garlipp
WWW: Kai Garlipp,
Frank S. Zollmann.
7.0 © 1995-2010 HUM-MOLGEN. All rights reserved.
Liability, Copyright and Imprint.